Novocure Q1 revenue rises 12%, beats analyst estimates; raises outlook

NovoCure

30/04/2026 12:12

Overview

Oncology device maker's Q1 revenue rose 12% yr/yr, beating analyst expectations

Company posted Q1 net loss of $71.1 mln, impacted by non-cash share-based compensation expense

Gross margin improved to 78% from 75% due to lower array costs and better utilization

Outlook

Novocure raises 2026 net revenue guidance to $690 mln-$710 mln from $675 mln-$705 mln

Company expects 2026 adjusted EBITDA between $(15) mln and $0 mln

Novocure anticipates topline data from Phase 3 TRIDENT trial in Q2 2026

Result Drivers

EUROPEAN PATIENT GROWTH - Co said revenue growth was primarily driven by active patient growth in European markets

ONE-TIME REVENUE BENEFITS - Revenue from Germany and France included one-time benefits of $2.5 mln and $1 mln, respectively

LOWER ARRAY COSTS - Gross margin improvement was driven by lower array costs from improved utilization and lower supplier prices

Company press release: ID:nBw8kLBtna

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$174.06 mln
$167.87 mln (6 Analysts)
Q1 Net Income
-$71.14 mln
Q1 Gross Profit
$135.13 mln
Q1 Operating Income
-$67.42 mln
Q1 Pretax Profit
-$69.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Novocure Ltd is $25.00, about 109.6% above its April 29 closing price of $11.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)